https://biotechmorning.com/news/merck-gardasil-factory-shutdown-durham Biotech Morning en 2026-05-15T14:26:26.625Z Merck Spent $1 Billion on a Vaccine Factory. Now It's Shutting It Down. https://biotechmorning.com/news/revolution-medicines-pancreatic-cancer-asco-2026 Biotech Morning en 2026-05-15T14:25:38.035Z The Cancer That Just Got a Lot Less Deadly https://biotechmorning.com/news/fda-new-boss-never-approved-drug Biotech Morning en 2026-05-15T14:24:41.769Z The FDA's New Boss Has Never Approved a Drug https://biotechmorning.com/news/100-percent-tariff-branded-drugs-domestic-manufacturing Biotech Morning en 2026-05-15T14:23:51.991Z The 100% Tax That Could Break Big Pharma's Global Playbook https://biotechmorning.com/news/ac-immune-ceo-departure-alzheimer-pipeline Biotech Morning en 2026-05-15T14:22:58.520Z AC Immune's 23-Year Captain Just Left the Ship. Now What? https://biotechmorning.com/news/aardvark-fda-hold-prader-willi-phase-3 Biotech Morning en 2026-05-15T14:22:00.076Z The Rare Disease Drug That Got Pulled Over for a Heart Check https://biotechmorning.com/news/create-medicines-122m-in-vivo-car-t Biotech Morning en 2026-05-15T14:21:10.238Z What If You Could Skip the Factory and Build CAR-T Cells Inside the Patient? https://biotechmorning.com/news/regenxbio-dmd-gene-therapy-beats-elevidys Biotech Morning en 2026-05-15T14:20:17.588Z The DMD Gene Therapy That's Blowing Elevidys Out of the Water https://biotechmorning.com/news/servier-acquires-day-one-biopharmaceuticals-pediatric-oncology Biotech Morning en 2026-05-15T14:19:21.895Z Why a French Pharma Giant Just Paid $2.5B to Fight Kids' Brain Tumors https://biotechmorning.com/news/gene-therapy-tumor-aav-safety-alarm Biotech Morning en 2026-05-15T14:18:25.782Z The Gene Therapy That Left a Tumor Behind https://biotechmorning.com/news/icon-san-antonio-clinical-research-unit-expansion Biotech Morning en 2026-05-14T14:16:07.658Z Why the Biggest CRO in the World Just Bet Big on San Antonio https://biotechmorning.com/news/lexicon-ceo-200m-pipeline-expansion Biotech Morning en 2026-05-14T14:15:17.721Z Lexicon's CEO Has $200M and a Wild Look in His Eye https://biotechmorning.com/news/beqalzi-sonrotoclax-fda-approval-mantle-cell-lymphoma Biotech Morning en 2026-05-14T14:14:25.502Z The Blood Cancer Drug That Picked Up Where Others Left Off https://biotechmorning.com/news/fosun-60m-aribio-alzheimers-option-deal Biotech Morning en 2026-05-14T14:13:36.142Z Fosun Just Bet $60M on an Alzheimer's Drug That Doesn't Work Like Anything Else https://biotechmorning.com/news/takeda-nausea-vomiting-0-for-4 Biotech Morning en 2026-05-14T14:12:42.366Z Takeda Can't Stop Striking Out in Nausea and Vomiting https://biotechmorning.com/news/assertio-bidding-war-sweetened-acquisition Biotech Morning en 2026-05-14T14:11:54.478Z The Bidding War That Turned a $18 Stock Into a $23.50 Payday https://biotechmorning.com/news/biogen-alzheimers-tau-drug-phase-3-despite-miss Biotech Morning en 2026-05-14T14:11:05.235Z Biogen's Alzheimer's Drug Failed Its Big Test. They're Going to Phase 3 Anyway. https://biotechmorning.com/news/us-biotechs-moving-trials-overseas-fda-upheaval Biotech Morning en 2026-05-14T14:10:11.315Z America's Biotechs Are Packing Their Bags. Here's Where They're Going.